Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists

Intratumoral immunotherapy strategies for cancer based on interleukin-12 (IL-12)-encoding cDNA and mRNA are under clinical development in combination with anti-PD-(L)1 monoclonal antibodies. To make the most of these approaches, we have constructed chimeric mRNAs encoding single-chain IL-12 fused to...

Descripción completa

Detalles Bibliográficos
Autores: Cirella, A. (Assunta)|||/items/398b3896-8ce3-4831-8ebc-1d86487cd790, Bolaños-Mateo, E. (Elixabet)|||/items/073a1977-5579-4bd1-8604-98b3ccfd4361, Luri-Rey, C. (Carlos)|||/items/efa6fd23-1164-4af9-8456-9c8fa4fddb8d, Di-Trani, C.A. (Claudia Augusta)|||/items/5d899126-779d-4c97-8232-95bfe18f9f26, Olivera-Valle, I. (Irene)|||/items/c3d06db0-d277-4fe8-9b33-59005441fec1, Gomis-Cobos, G. (Gabriel)|||/items/c756710a-4f47-4acf-a13a-b47c739cef8c, Pinci, B. (Beatrice)|||/items/319d608a-6b4d-4209-9582-8cdabd7f017c, Garasa, S. (Saray)|||/items/51924af8-57aa-477c-b3d8-886422be3713, Sánchez-Gregorio, S. (Sandra)|||/items/0e87cc21-b1fc-49eb-891c-c1a9e6183b5e, Azpilikueta, A. (Arantza)|||/items/8cb8f9c3-bb52-41cc-a19d-03de632308e9, Eguren-Santamaría, I. (Iñaki)|||/items/a597d707-9f63-46ab-8da1-e99ed05e644e, Valencia, K. (Karmele)|||/items/bf771eab-81c1-4221-80f5-87713ad5e51f, Palencia-Coto, B. (Belén)|||/items/c439a2a6-fad9-4a0b-8309-ceca8c25edf2, Álvarez-Rodríguez, M. (Maite)|||/items/e298edcf-2e7f-4001-a5e2-244efa1a7781, Ochoa-Nieto, M.C. (María del Carmen)|||/items/a26293bb-e79a-42a3-be52-dbf5208f3f89, Teijeira-Sánchez, A. (Álvaro)|||/items/8a954ec4-8458-46ea-b8e6-3165119bef30, Berraondo-López, P. (Pedro)|||/items/b1f8ccc3-8e08-4ece-967c-64ccfc0e5b91, Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e, González-Vaz, J. (Javier)|||/items/9d321bb0-f713-4608-8d35-15b1c9588b76
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/67856
Acceso en línea:https://hdl.handle.net/10171/67856
Access Level:acceso abierto
Palabra clave:4-1BB
CD137
IL-12
MT: Delivery Strategies
TGF-β
Local immunotherapy
mRNA
id ES_dce18d5be3a731dddbcc16d5ab08aa2e
oai_identifier_str oai:dadun.unav.edu:10171/67856
network_acronym_str ES
network_name_str España
repository_id_str
spelling Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonistsCirella, A. (Assunta)|||/items/398b3896-8ce3-4831-8ebc-1d86487cd790Bolaños-Mateo, E. (Elixabet)|||/items/073a1977-5579-4bd1-8604-98b3ccfd4361Luri-Rey, C. (Carlos)|||/items/efa6fd23-1164-4af9-8456-9c8fa4fddb8dDi-Trani, C.A. (Claudia Augusta)|||/items/5d899126-779d-4c97-8232-95bfe18f9f26Olivera-Valle, I. (Irene)|||/items/c3d06db0-d277-4fe8-9b33-59005441fec1Gomis-Cobos, G. (Gabriel)|||/items/c756710a-4f47-4acf-a13a-b47c739cef8cPinci, B. (Beatrice)|||/items/319d608a-6b4d-4209-9582-8cdabd7f017cGarasa, S. (Saray)|||/items/51924af8-57aa-477c-b3d8-886422be3713Sánchez-Gregorio, S. (Sandra)|||/items/0e87cc21-b1fc-49eb-891c-c1a9e6183b5eAzpilikueta, A. (Arantza)|||/items/8cb8f9c3-bb52-41cc-a19d-03de632308e9Eguren-Santamaría, I. (Iñaki)|||/items/a597d707-9f63-46ab-8da1-e99ed05e644eValencia, K. (Karmele)|||/items/bf771eab-81c1-4221-80f5-87713ad5e51fPalencia-Coto, B. (Belén)|||/items/c439a2a6-fad9-4a0b-8309-ceca8c25edf2Álvarez-Rodríguez, M. (Maite)|||/items/e298edcf-2e7f-4001-a5e2-244efa1a7781Ochoa-Nieto, M.C. (María del Carmen)|||/items/a26293bb-e79a-42a3-be52-dbf5208f3f89Teijeira-Sánchez, A. (Álvaro)|||/items/8a954ec4-8458-46ea-b8e6-3165119bef30Berraondo-López, P. (Pedro)|||/items/b1f8ccc3-8e08-4ece-967c-64ccfc0e5b91Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4eGonzález-Vaz, J. (Javier)|||/items/9d321bb0-f713-4608-8d35-15b1c9588b764-1BBCD137IL-12MT: Delivery StrategiesTGF-βLocal immunotherapymRNAIntratumoral immunotherapy strategies for cancer based on interleukin-12 (IL-12)-encoding cDNA and mRNA are under clinical development in combination with anti-PD-(L)1 monoclonal antibodies. To make the most of these approaches, we have constructed chimeric mRNAs encoding single-chain IL-12 fused to single-chain fragment variable (scFv) antibodies that bind to transforming growth factor b (TGF-b) and CD137 (4-1BB). Several neutralizing TGF- b agents and CD137 agonists are also undergoing early-phase clinical trials. To attain TGF-beta and CD137 binding by the constructions, we used bispecific tandem scFv antibodies (taFvs) derived from the specific 1D11 and 1D8 monoclonal antibodies (mAbs), respectively. Transfection of mRNAs encoding the chimeric constructs achieved functional expression of the proteins able to act on their targets. Upon mRNA intratumoral injections in the transplantable mouse cancer models CT26, MC38, and B16OVA, potent therapeutic effects were observed following repeated injections into the tumors. Efficacy was dependent on the number of CD8+ T cells able to recognize tumor antigens that infiltrated the malignant tissue. Although the abscopal effects on concomitant uninjected lesions were modest, such distant effects on untreated lesions were markedly increased when combined with systemic PD-1 blockade.Dadun. Depósito Académico Digital Universidad de Navarra20232023-11-1520232023-01-0120232023-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/67856reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/678562026-06-21T12:47:57Z
dc.title.none.fl_str_mv Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
title Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
spellingShingle Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
Cirella, A. (Assunta)|||/items/398b3896-8ce3-4831-8ebc-1d86487cd790
4-1BB
CD137
IL-12
MT: Delivery Strategies
TGF-β
Local immunotherapy
mRNA
title_short Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
title_full Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
title_fullStr Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
title_full_unstemmed Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
title_sort Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-ß antagonists
dc.creator.none.fl_str_mv Cirella, A. (Assunta)|||/items/398b3896-8ce3-4831-8ebc-1d86487cd790
Bolaños-Mateo, E. (Elixabet)|||/items/073a1977-5579-4bd1-8604-98b3ccfd4361
Luri-Rey, C. (Carlos)|||/items/efa6fd23-1164-4af9-8456-9c8fa4fddb8d
Di-Trani, C.A. (Claudia Augusta)|||/items/5d899126-779d-4c97-8232-95bfe18f9f26
Olivera-Valle, I. (Irene)|||/items/c3d06db0-d277-4fe8-9b33-59005441fec1
Gomis-Cobos, G. (Gabriel)|||/items/c756710a-4f47-4acf-a13a-b47c739cef8c
Pinci, B. (Beatrice)|||/items/319d608a-6b4d-4209-9582-8cdabd7f017c
Garasa, S. (Saray)|||/items/51924af8-57aa-477c-b3d8-886422be3713
Sánchez-Gregorio, S. (Sandra)|||/items/0e87cc21-b1fc-49eb-891c-c1a9e6183b5e
Azpilikueta, A. (Arantza)|||/items/8cb8f9c3-bb52-41cc-a19d-03de632308e9
Eguren-Santamaría, I. (Iñaki)|||/items/a597d707-9f63-46ab-8da1-e99ed05e644e
Valencia, K. (Karmele)|||/items/bf771eab-81c1-4221-80f5-87713ad5e51f
Palencia-Coto, B. (Belén)|||/items/c439a2a6-fad9-4a0b-8309-ceca8c25edf2
Álvarez-Rodríguez, M. (Maite)|||/items/e298edcf-2e7f-4001-a5e2-244efa1a7781
Ochoa-Nieto, M.C. (María del Carmen)|||/items/a26293bb-e79a-42a3-be52-dbf5208f3f89
Teijeira-Sánchez, A. (Álvaro)|||/items/8a954ec4-8458-46ea-b8e6-3165119bef30
Berraondo-López, P. (Pedro)|||/items/b1f8ccc3-8e08-4ece-967c-64ccfc0e5b91
Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e
González-Vaz, J. (Javier)|||/items/9d321bb0-f713-4608-8d35-15b1c9588b76
author Cirella, A. (Assunta)|||/items/398b3896-8ce3-4831-8ebc-1d86487cd790
author_facet Cirella, A. (Assunta)|||/items/398b3896-8ce3-4831-8ebc-1d86487cd790
Bolaños-Mateo, E. (Elixabet)|||/items/073a1977-5579-4bd1-8604-98b3ccfd4361
Luri-Rey, C. (Carlos)|||/items/efa6fd23-1164-4af9-8456-9c8fa4fddb8d
Di-Trani, C.A. (Claudia Augusta)|||/items/5d899126-779d-4c97-8232-95bfe18f9f26
Olivera-Valle, I. (Irene)|||/items/c3d06db0-d277-4fe8-9b33-59005441fec1
Gomis-Cobos, G. (Gabriel)|||/items/c756710a-4f47-4acf-a13a-b47c739cef8c
Pinci, B. (Beatrice)|||/items/319d608a-6b4d-4209-9582-8cdabd7f017c
Garasa, S. (Saray)|||/items/51924af8-57aa-477c-b3d8-886422be3713
Sánchez-Gregorio, S. (Sandra)|||/items/0e87cc21-b1fc-49eb-891c-c1a9e6183b5e
Azpilikueta, A. (Arantza)|||/items/8cb8f9c3-bb52-41cc-a19d-03de632308e9
Eguren-Santamaría, I. (Iñaki)|||/items/a597d707-9f63-46ab-8da1-e99ed05e644e
Valencia, K. (Karmele)|||/items/bf771eab-81c1-4221-80f5-87713ad5e51f
Palencia-Coto, B. (Belén)|||/items/c439a2a6-fad9-4a0b-8309-ceca8c25edf2
Álvarez-Rodríguez, M. (Maite)|||/items/e298edcf-2e7f-4001-a5e2-244efa1a7781
Ochoa-Nieto, M.C. (María del Carmen)|||/items/a26293bb-e79a-42a3-be52-dbf5208f3f89
Teijeira-Sánchez, A. (Álvaro)|||/items/8a954ec4-8458-46ea-b8e6-3165119bef30
Berraondo-López, P. (Pedro)|||/items/b1f8ccc3-8e08-4ece-967c-64ccfc0e5b91
Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e
González-Vaz, J. (Javier)|||/items/9d321bb0-f713-4608-8d35-15b1c9588b76
author_role author
author2 Bolaños-Mateo, E. (Elixabet)|||/items/073a1977-5579-4bd1-8604-98b3ccfd4361
Luri-Rey, C. (Carlos)|||/items/efa6fd23-1164-4af9-8456-9c8fa4fddb8d
Di-Trani, C.A. (Claudia Augusta)|||/items/5d899126-779d-4c97-8232-95bfe18f9f26
Olivera-Valle, I. (Irene)|||/items/c3d06db0-d277-4fe8-9b33-59005441fec1
Gomis-Cobos, G. (Gabriel)|||/items/c756710a-4f47-4acf-a13a-b47c739cef8c
Pinci, B. (Beatrice)|||/items/319d608a-6b4d-4209-9582-8cdabd7f017c
Garasa, S. (Saray)|||/items/51924af8-57aa-477c-b3d8-886422be3713
Sánchez-Gregorio, S. (Sandra)|||/items/0e87cc21-b1fc-49eb-891c-c1a9e6183b5e
Azpilikueta, A. (Arantza)|||/items/8cb8f9c3-bb52-41cc-a19d-03de632308e9
Eguren-Santamaría, I. (Iñaki)|||/items/a597d707-9f63-46ab-8da1-e99ed05e644e
Valencia, K. (Karmele)|||/items/bf771eab-81c1-4221-80f5-87713ad5e51f
Palencia-Coto, B. (Belén)|||/items/c439a2a6-fad9-4a0b-8309-ceca8c25edf2
Álvarez-Rodríguez, M. (Maite)|||/items/e298edcf-2e7f-4001-a5e2-244efa1a7781
Ochoa-Nieto, M.C. (María del Carmen)|||/items/a26293bb-e79a-42a3-be52-dbf5208f3f89
Teijeira-Sánchez, A. (Álvaro)|||/items/8a954ec4-8458-46ea-b8e6-3165119bef30
Berraondo-López, P. (Pedro)|||/items/b1f8ccc3-8e08-4ece-967c-64ccfc0e5b91
Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e
González-Vaz, J. (Javier)|||/items/9d321bb0-f713-4608-8d35-15b1c9588b76
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv 4-1BB
CD137
IL-12
MT: Delivery Strategies
TGF-β
Local immunotherapy
mRNA
topic 4-1BB
CD137
IL-12
MT: Delivery Strategies
TGF-β
Local immunotherapy
mRNA
description Intratumoral immunotherapy strategies for cancer based on interleukin-12 (IL-12)-encoding cDNA and mRNA are under clinical development in combination with anti-PD-(L)1 monoclonal antibodies. To make the most of these approaches, we have constructed chimeric mRNAs encoding single-chain IL-12 fused to single-chain fragment variable (scFv) antibodies that bind to transforming growth factor b (TGF-b) and CD137 (4-1BB). Several neutralizing TGF- b agents and CD137 agonists are also undergoing early-phase clinical trials. To attain TGF-beta and CD137 binding by the constructions, we used bispecific tandem scFv antibodies (taFvs) derived from the specific 1D11 and 1D8 monoclonal antibodies (mAbs), respectively. Transfection of mRNAs encoding the chimeric constructs achieved functional expression of the proteins able to act on their targets. Upon mRNA intratumoral injections in the transplantable mouse cancer models CT26, MC38, and B16OVA, potent therapeutic effects were observed following repeated injections into the tumors. Efficacy was dependent on the number of CD8+ T cells able to recognize tumor antigens that infiltrated the malignant tissue. Although the abscopal effects on concomitant uninjected lesions were modest, such distant effects on untreated lesions were markedly increased when combined with systemic PD-1 blockade.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-11-15
2023
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/67856
url https://hdl.handle.net/10171/67856
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421809358602240
score 15,300724